



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 02 Sep 2019 (#29)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices & News

- **Report on Reducing Administrative Burden for Researchers: Animal Care and Use in Research ([NOT-OD-19-136](#))**
- **Sexual and Gender Minority Populations in NIH-Supported Research ([NOT-OD-19-139](#))**. The purpose of this Notice is to announce the revision of the definition of sexual and gender minority (SGM) populations for research purposes at the NIH, as well as to provide a summary of information about SGM health research at the NIH.
- **Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program ([NOT-TW-19-007](#))** The purpose of this Notice is to announce that the NIH is collaborating on the multi-agency funding opportunity, the Ecology and Evolution of Infectious Diseases (EEID) ([NSF-19-592](#)). This Notice updates and supersedes the previous Guide Notice, [NOT-TW-18-005](#), published in the NIH Guide, October 23, 2018.
- **Notice of Special Interest (NOSI): Epidemiology of Drug Abuse ([NOT-DA-19-066](#))** The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Priority will be given to applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes.
- **Notice of Special Interest in X-ray-based Devices for Trauma Care ([NOT-EB-19-015](#))** The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing portable x-ray imaging devices for application in trauma care.
- **Notice of Special Interest in Ultrasound and Optics-based Devices for Trauma Care ([NOT-EB-19-016](#))** The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB), of an area of special interest in developing portable ultrasound and optic devices for application in trauma care.
- **Notice of Special Interest in Radiation Monitoring for Trauma Care ([NOT-EB-19-017](#))** The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing radiation sensors for application in trauma care.
- **Notice of Special Interest in Physiological Monitoring and Point of Care Technologies for Trauma Care ([NOT-EB-19-018](#))** The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing physiological sensors for application in trauma care.

### 1. Neural Regulation of Cancer (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-353](#)  
[PAR-19-354](#)

**Type:** R01  
R21

**Application Due Date:** October 21, 2019; May 27, 2020; October 21, 2020; May 27, 2021; October 21, 2021; May 27, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

**Budget: R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 2. NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-356](#)

**Type:** R21

**Application Due Date:** October 18, 2019; February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022. **AIDS dates:** December 18, 2019; March 20, 2020; July 20, 2020; December 18, 2020; March 19, 2021; July 20, 2021; December 17, 2021; March 21, 2022; July 20, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 3. Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-361](#)

**Type:** U01

**Application Due Date:** November 12, 2019; March 11, 2020; November 12, 2020; March 11, 2021; November 12, 2021; March 11, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.

**Budget:** Budgets are limited to \$450,000 Direct Costs (excluding consortium F&A costs) per year. Budgets should reflect the actual needs of the proposed project and non-modular budgets require extensive justification. The maximum project period is five years

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizel*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105